About Bone Biologics Corporation
http://www.bonebiologics.comBone Biologics Corporation, a medical device company, focuses on bone regeneration in spinal fusion using the recombinant human protein. Its NELL-1/DBX is a combination product, which is an osteostimulative recombinant protein that provides target specific control over bone regeneration.
CEO
Jeffrey Frelick
Compensation Summary
(Year 2022)
Salary $300,000
Option Awards $76,965
Incentive Plan Pay $37,750
Total Compensation $414,715
Industry Medical - Devices
Sector Healthcare
Went public October 13, 2021
Method of going public IPO
Full time employees 2
Split Record
| Date | Type | Ratio |
|---|---|---|
| 2025-06-10 | Reverse | 1:6 |
| 2023-06-07 | Reverse | 1:30 |
Ratings Snapshot
Rating : C-
Discounted Cash Flow 3
Return On Equity 1
Return On Assets 1
Debt To Equity 1
Price To Earnings 1
Price To Book 2
Overall Score 1
Price Target
Target High $0
Target Low $0
Target Median $0
Target Consensus $0
Institutional Ownership
Summary
% Of Shares Owned 7.82%
Total Number Of Holders 1
Showing Top 1 of 1
Market Cap $22.44 M
52w High $95.04
52w Low $4.70
P/E -102.08
Volume 8
Outstanding Shares 1.80M
About Bone Biologics Corporation
http://www.bonebiologics.comBone Biologics Corporation, a medical device company, focuses on bone regeneration in spinal fusion using the recombinant human protein. Its NELL-1/DBX is a combination product, which is an osteostimulative recombinant protein that provides target specific control over bone regeneration.
Income Statement
| Period | Revenue | Operating Expense | Net Income | Net Profit Margin | Earnings Per Share | EBITDA |
|---|---|---|---|---|---|---|
| Q3-2025 | $0 | $715.27K ▼ | $-666.74K ▲ | 0% | $-0.37 ▲ | $48.54K ▲ |
| Q2-2025 | $0 | $748.08K ▼ | $-740.52K ▲ | 0% | $-1.33 ▼ | $-748.08K ▲ |
| Q1-2025 | $0 | $1.04M ▼ | $-1.02M ▲ | 0% | $-0.32 ▲ | $-1.02M ▲ |
| Q4-2024 | $0 | $1.55M ▲ | $-1.52M ▼ | 0% | $-0.48 ▲ | $-1.52M ▼ |
| Q3-2024 | $0 | $951.02K | $-941K | 0% | $-2.37 | $-941K |
Balance Statement
| Period | Cash & Short-term | Total Assets | Total Liabilities | Total Equity |
|---|---|---|---|---|
| Q3-2025 | $6.05M ▼ | $6.35M ▼ | $334.28K ▼ | $6.02M ▼ |
| Q2-2025 | $6.64M ▲ | $7M ▲ | $406.14K ▲ | $6.6M ▲ |
| Q1-2025 | $2.75M ▼ | $3.16M ▼ | $251.16K ▼ | $2.91M ▼ |
| Q4-2024 | $3.33M ▼ | $3.86M ▼ | $377.71K ▲ | $3.48M ▼ |
| Q3-2024 | $3.57M | $4.07M | $273.4K | $3.79M |
Cash Flow Statement
| Period | Net Income | Cash From Operations | Cash From Investing | Cash From Financing | Net Change | Free Cash Flow |
|---|---|---|---|---|---|---|
| Q3-2025 | $-666.74K ▲ | $-591.38K ▼ | $0 | $0 ▼ | $-591.38K ▼ | $-591.38K ▼ |
| Q2-2025 | $-740.52K ▲ | $-458.88K ▲ | $0 | $4.35M ▲ | $3.89M ▲ | $-458.88K ▲ |
| Q1-2025 | $-1.02M ▲ | $-926.13K ▲ | $0 | $347.55K ▼ | $-578.58K ▼ | $-926.12K ▲ |
| Q4-2024 | $-1.52M ▼ | $-1.35M ▼ | $0 | $1.11M ▼ | $-241.29K ▼ | $-1.35M ▼ |
| Q3-2024 | $-941K | $-572.16K | $0 | $1.81M | $1.23M | $-572.16K |
CEO
Jeffrey Frelick
Compensation Summary
(Year 2022)
Salary $300,000
Option Awards $76,965
Incentive Plan Pay $37,750
Total Compensation $414,715
Industry Medical - Devices
Sector Healthcare
Went public October 13, 2021
Method of going public IPO
Full time employees 2
Split Record
| Date | Type | Ratio |
|---|---|---|
| 2025-06-10 | Reverse | 1:6 |
| 2023-06-07 | Reverse | 1:30 |
Ratings Snapshot
Rating : C-
Discounted Cash Flow 3
Return On Equity 1
Return On Assets 1
Debt To Equity 1
Price To Earnings 1
Price To Book 2
Overall Score 1
Price Target
Target High $0
Target Low $0
Target Median $0
Target Consensus $0
Institutional Ownership
Summary
% Of Shares Owned 7.82%
Total Number Of Holders 1
Showing Top 1 of 1